Synthesis of Ahf in Von Willebrand's Disease.
نویسنده
چکیده
BLOOD, VOL. 23, No. 2 (FEBRUARY), 1964 By Jitssic & H. Li wis A HEMORRAGIC DISEASE, first described by von Willebrand in 1926’ in a large family living on the Aland Islands, has gone through a fascinating diagnostic metamorphosis. Initially it was thought to be due to a platelet abnormality,2’3 later to a vascular abnormality;4’5 more recently, to lack of a plasma factor( s ) .#{176} ‘ This changing pathogenetic view reflects not only increasing diagnostic skill but also inclusion in some publications of patients with varying hemostatic defects. In 1957, Nilsson and co-workers7 studied 15 members of the original family on the Aland Islands and found mild AHF (factor VIII ) deficiency in all bleeders and prolonged bleeding times in those with moderate to severe hemorrhagic symptoms. Other tests, including those of platelet function, were normal. In one patient the prolonged bleeding time was corrected by an infusion of plasma fraction 1-0. Thus it seemed possible to re-define von Willebrand’s disease as a hemorrhagic disorder, usually familial, characterized by a prolonged bleeding time and a low level of AHF. With this definition in mind, descriptions of many similar cases can be found in the literature including those in which the disease has been called “vascular hemophilia,” “pseudohemophilia B” and “angiohemophilia A.” The patient presented herewith appears to fall within the definition of von Willebrand’s disease although she lacks a positive family history. Of particular importance is the apparent ability of this patient to synthesize her own AHF when infused with normal or hemophulic plasma.
منابع مشابه
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
In a previous paper, we showed that the abnormality of ristocetin-induced platelet aggregation in platelet-rich plasma in 10 patients with von Willebrand's disease could be corrected by a factor in normal plasma that was present in the same fractions as factor VIII procoagulant activity (antihemophilic factor, AHF, VIII(AHF)) when prepared by chromatography on Bio-Gel 5 M (Bio-Rad Laboratories,...
متن کاملStabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
In normal plasma, the ratio of the procoagulant activity of factor VIII (VIII(AHF)) to that of the von Willebrand factor activity (ristocetin cofactor, VIII(VWF)) or factor VIII antigen (VIII(AGN)) is approximately 1, but ratios > 1 (e.g., VIII(AHF) > VIII(VWF) or VIII(AGN)) may be observed in some patients with von Willebrand's disease and in the "late" posttransfusion plasmas of patients with...
متن کاملDefective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
The antibiotic ristocetin, in concentrations of 1.0-1.5 mg/ml, aggregated normal platelets in citrated platelet-rich plasma by a mechanism in which the release reaction played only a minor role. Platelet aggregation by ristocetin in a concentration of 1.2 mg/ml was absent or markedly decreased in 10 patients with von Willebrand's disease. Lesser degrees of abnormality were obtained with a conce...
متن کاملStudies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.
Normal human antihemophilic factor (AHF, factor VIII) and the protein antigenically related to it in hemophilic plasma both appeared in the void volume of columns of agarose (Sepharose 4B) during purification of these agents. On ultracentrifugation upon sucrose gradients, both agents had sedimentation characteristics similar to those of an S30 marker. After reduction, the polypeptide chains of ...
متن کاملThe relationship of the properties of antihemophilic factor (factor VIII) that support ristocetin-induced platelet agglutination (factor VIIIR:RC) and platelet retention by glass beads as demonstrated by a monoclonal antibody.
A monoclonal antibody to human antihemophilic factor (AHF, factor VIII) was derived from BALB/c mouse spleen cells fused with P3x63Ag8 mouse plasmacytoma cells. This antibody, harvested from culture medium or ascites fluid, reacted with purified AHF and with plasmas with normal subjects or classic hemophiliacs, as measured by enzyme-linked immunosorbent assay (ELISA), but not with plasmas from ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 23 شماره
صفحات -
تاریخ انتشار 1964